EPISODE · Nov 12, 2024 · 5 MIN
Clinic Conversation of the Week: How to Talk to Patients About the BENEFIT Trial in Multiple Myeloma
from Oncology Data Advisor · host i3 Health
The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?
What this episode covers
The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?
NOW PLAYING
Clinic Conversation of the Week: How to Talk to Patients About the BENEFIT Trial in Multiple Myeloma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.